Abstract: A measurement system includes a measurement device including a light source, and a first power meter, and one or a plurality of connection members each configured to optically connect a pair of optical fiber lines of the plurality of optical fiber lines. A first optical fiber line of the pair of optical fiber lines includes a first end and a second end, a second optical fiber line of the pair of optical fiber lines includes a third end and a fourth end, the one or plurality of connection members optically connect the second end to the fourth end, the light source causes testing light to be incident on the first end, and the first power meter measures first intensity of first output light output from the third end by causing the testing light to propagate through the pair of optical fiber lines.

Abstract: An in-vehicle network system deployed in a vehicle includes a plurality of first nodes configured to perform an operation relevant to a first function in the vehicle, a second node configured to perform an operation relevant to a second function different from the first function in the vehicle; and a relay device configured to relay communication between the first nodes and the second node. The relay device is configured to start relay of communication between the first nodes earlier than the relay of communication between the first node and the second node at a time of startup.

Abstract: [PROBLEM] The problem to be solved by the invention is to provide a novel pharmaceutical use of a JAK inhibitor. [SOLUTION MEANS] A therapeutic or preventive agent for a skin disease selected from the group consisting of senile xerosis, asteatosis, eczema and contact dermatitis, containing a JAK inhibitor as an active ingredient. [EFFECT] The followings are found: a JAK inhibitor increases the expression amounts of filaggrin, loricrin, involucrin and ?-defensin 3 as skin barrier function-related proteins; a JAK inhibitor significantly increases NMF production in a Tape Stripping-treated mouse; and a JAK inhibitor significantly accelerates a reduction in TEWL in a dry skin mouse model, namely improves the skin barrier function. The JAK inhibitor can be used as an active ingredient of a therapeutic or preventive agent for skin diseases such as senile xerosis, asteatosis, eczema, contact dermatitis, ichthyosis vulgaris, Netherton syndrome, type B peeling skin syndrome, etc.

Abstract: Provided is a therapeutic or prophylactic agent for pain or interstitial cystitis comprising N-[2-(6,6-dimethyl-4,5,6,7-tetrahydro-H-indazol-3-yl)-1H-indol-6-yl]-N-methyl-(2S)-2-(morpholin-4-yl)propanamide or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides a therapeutic agent or prophylactic agent for nephrotic syndrome, containing N-[2-(6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1H-indol-6-yl]-N-methyl-(2S)-2-(morpholin-4-yl)propanamide or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides a therapeutic agent or prophylactic agent for multiple sclerosis, containing N-[2-(6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1H-indol-6-yl]-N-methyl-(2S)-2-(morpholin-4-yl)propanamide or a pharmaceutically acceptable salt thereof.

Abstract: [PROBLEM] The problem to be solved by the invention is to provide a novel pharmaceutical use of a JAK inhibitor. [SOLUTION MEANS] A therapeutic or preventive agent for a skin disease selected from the group consisting of senile xerosis, asteatosis, eczema and contact dermatitis, containing a JAK inhibitor as an active ingredient. [EFFECT] The followings are found: a JAK inhibitor increases the expression amounts of filaggrin, loricrin, involucrin and ?-defensin 3 as skin barrier function-related proteins; a JAK inhibitor significantly increases NMF production in a Tape Stripping-treated mouse; and a JAK inhibitor significantly accelerates a reduction in TEWL in a dry skin mouse model, namely improves the skin barrier function. The JAK inhibitor can be used as an active ingredient of a therapeutic or preventive agent for skin diseases such as senile xerosis, asteatosis, eczema, contact dermatitis, ichthyosis vulgaris, Netherton syndrome, type B peeling skin syndrome, etc.

Abstract: Provided is a therapeutic or prophylactic agent for pain or interstitial cystitis comprising N-[2-(6,6-dimethyl-4,5,6,7-tetrahydro-H-indazol-3-yl)-1H-indol-6-yl]-N-methyl-(2S)-2-(morpholin-4-yl)propanamide or a pharmaceutically acceptable salt thereof.

Abstract: The invention provides a method for treating or preventing a skin disease, such as senile xerosis, asteatosis, eczema, contact dermatitis, ichthyosis vulgaris, Netherton syndrome, and type B peeling skin syndrome, by administering an effective amount of a JAK inhibitor to a mammal in need thereof. The invention also provides methods of improving skin barrier function, increasing transcription of a gene, and increasing production of a protein in a mammal by administering an effective amount of a JAK inhibitor to the mammal.

Abstract: [PROBLEM] The problem to be solved by the invention is to provide a novel pharmaceutical use of a JAK inhibitor. [SOLUTION MEANS] A therapeutic or preventive agent for a skin disease selected from the group consisting of senile xerosis, asteatosis, eczema and contact dermatitis, containing a JAK inhibitor as an active ingredient. [EFFECT] The followings are found: a JAK inhibitor increases the expression amounts of filaggrin, loricrin, involucrin and ?-defensin 3 as skin barrier function-related proteins; a JAK inhibitor significantly increases NMF production in a Tape Stripping-treated mouse; and a JAK inhibitor significantly accelerates a reduction in TEWL in a dry skin mouse model, namely improves the skin barrier function. The JAK inhibitor can be used as an active ingredient of a therapeutic or preventive agent for skin diseases such as senile xerosis, asteatosis, eczema, contact dermatitis, ichthyosis vulgaris, Netherton syndrome, type B peeling skin syndrome, etc.

Abstract: [PROBLEM] The problem to be solved by the invention is to provide a novel pharmaceutical use of a JAK inhibitor. [SOLUTION MEANS] A therapeutic or preventive agent for a skin disease selected from the group consisting of senile xerosis, asteatosis, eczema and contact dermatitis, containing a JAK inhibitor as an active ingredient. [EFFECT] The followings are found: a JAK inhibitor increases the expression amounts of filaggrin, loricrin, involucrin and ?-defensin 3 as skin barrier function-related proteins; a JAK inhibitor significantly increases NMF production in a Tape Stripping-treated mouse; and a JAK inhibitor significantly accelerates a reduction in TEWL in a dry skin mouse model, namely improves the skin barrier function. The JAK inhibitor can be used as an active ingredient of a therapeutic or preventive agent for skin diseases such as senile xerosis, asteatosis, eczema, contact dermatitis, ichthyosis vulgaris, Netherton syndrome, type B peeling skin syndrome, etc.

Abstract: An objective of the present invention is to provide novel therapeutic agents for non-immediate-type allergic diseases that comprise, as an active ingredient, a cannabinoid receptor modulator, particularly that selectively acts on peripheral cell type cannabinoid receptors (CB2), and more particularly an inverse agonist.

Abstract: In accordance with the invention, a therapeutic agent of allergic disease is provided, which contains a cannabinoid receptor-regulating substance, particularly a regulating substance selectively acting on peripheral cell type cannabinoid receptor, specifically N-(benzo[1,3]dioxol-5-ylmethyl)-7-methoxy-2-oxo-8-pentyloxy-1,2-dihydroquinoline-3-carboxamide or a pharmaceutically acceptable salt thereof; and the therapeutic agent of the invention shows effects on intractable allergic disease, for example asthma and atopic dermatitis.

Abstract: An all-solid-state tunable pulse laser using a titanium-doped sapphire single crystal in which a pumping source is a pulse beam, which is produced by doubling with a KTiOPO.sub.4 under a 90.degree. phase matching condition a Q-switching laser pulse of a light beam, which is produced by a transition of .sup.4 F.sub.3/2 .fwdarw..sup.4 I.sub.11/2 in a neodymium-doped yttrium aluminum perovskite crystal pumped with a quasi-continuous diode laser.

Abstract: A reel drive apparatus for selectively driving a pair of the reel turntables. The apparatus includes a shaft, a pulley rotatably mounted on the shaft, a sun gear fixed coaxially to the pulley, a planet gear engaged with the sun gear, a planet gear holder rotatably supported on the shaft for supporting the planet gear, an internal gear rotatably mounted on the shaft and engaged with the planet gear, an outer gear fixed coaxially to the internal gear, an idler arm rockably mounted its one end on the shaft, an idler gear mounted to another end of the idler arm and engaged with the outer gear and a clutch for selectively transmitting a driving force to the planet gear holder.

Abstract: A selective drive cartridge loading/unloading apparatus connects one motor with multiple driving objects. A worm gear is mounted on the motor shaft in such a manner that it rotates together with the shaft and can move axially along the shaft. The worm gear meshes with different power transmission mechanisms when it is at different points along the shaft.